Myeloma Clinical Trial Guide: What Endpoints Mean for You image

Myeloma Clinical Trial Guide: What Endpoints Mean for You

Posted by

HealthTree

Last updated and reviewed on: January 07, 2025

This guide helps multiple myeloma patients and their loved ones understand clinical trial endpoints, aiding in interpreting clinical data and choosing the right trial. Medically Reviewed by Dr. Adeel Khan

Introduction

This section explains the purpose of the educational guide and how to navigate it.

How Clinical Trial Endpoints Shape Therapy Approvals and What They Mean for You

This section explains how clinical trial endpoints shape FDA approvals for treatments and why understanding endpoints is important to patients.

So, What Is an Endpoint?

This section briefly explains what an endpoint is.

Understanding Primary and Secondary Endpoints

This section explains what primary and secondary endpoints are in clinical trials.

Understanding Surrogate Endpoints

This section explains surrogate endpoints and what they mean in clinical trials.

What are Common Endpoints in Myeloma Clinical Trials?

This section explains common endpoints in myeloma clinical trials, like overall survival and progression-free survival.

Progression-Free Survival (PFS)

This section explains progression-free surivival, or PFS.

Overall Response Rate (ORR)

This section explains overall response rate (ORR), a common endpoint in myeloma clinical trials.

Overall Survival (OS)

This section explains overall survival, or OS, a common endpoint in myeloma clinical trials.

Safety and Tolerability

This section explains safety and tolerability, the main focus of early phase clinical trials.

Quality of Life (QoL)

This section explains quality of life, or QoL, a common endpoint in myeloma clinical trials.

Minimal Residual Disease (MRD)

This section explains minimal residual disease, or MRD, and how its used as an endpoint in myeloma clinical trials.

Patient-Related Outcomes and Real-World Data

This section explains what patient-related outcomes, or PROs, are in the context of clinical trials, and how they are used.

Other Clinical Trial Endpoints

This section explains other clinical trial endpoints, like duration of response or DoR, and time to progression, TTP.

How Are Clinical Trial Phases and their Endpoints Related?

This section explains how clinical trial endpoints and the phase of the clinical trial are related.

Phase I: Safety and Tolerability

This section explains Phase I clinical trials, whose endpoints are usually associated with safety and tolerability.

Phase II: Efficacy and Dosage

This section covers Phase II trials, whose endpoints normally focus on efficacy and dosage.

Phase III: Comparison to Standard-of-Care

This section covers Phase III clinical trials, whose endpoints are associated with the approval of a treatment.

Phase IV: After-Market Observations

This section explains Phase IV clinical trials, which are conducted after the treatment has been approved.

Clinical Trial Design and Other Terminology

This section explains the design of clinical trials and clarifies important terminology around clinical trials.

Understanding Clinical Trial Design

This section explains how clinical trials are designed, including the different types of trials that exist.

Key Terms

This section clarifies vocabulary surrounding clinical trials.

Clinical Trial Myths

This section debunks myths surrounding clinical trials that might keep someone from participating in one.

Why Participate in Clinical Trials?

This section explains reasons behind why people participate in clinical trials and real world data opportunities.

Why Others Participate In Myeloma Clinical Trials and Research

This section explains why others participate in myeloma research.

Questions to Ask Your Doctor

This section contains questions to ask your doctor about clinical trials.

Resources

This is a section for HealthTree and external resources and references used throughout this guide.

Related Content